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Abstract 
 
Background: The trigeminovascular theory suggests that neurogenic inflammation and 
cytokines play an important role in migraine pathophysiology. Previous studies have linked 
different cytokines to migraine pathogenesis, but the results have been conflicting. Today, no 
biomarkers are known for primary headaches.  The objectives for this thesis were to: 1. 
Identify cytokines as possible specific biomarkers for migraine, cluster headache and tension-
type headache. 2. Define cytokine secretion as possible inflammatory response to pain. 3. 
Evaluate the use of ELISA assay and ELISpot assay for the purpose of this study. 4. Evaluate 
strengths and flaws of this pilot study and suggest improvements for future studies. 
 
Methods: Too few tension-type headache patients, and no cluster headache patients, agreed 
to participate in this study. The only headache group consisted of 11 migraineurs. Control 
groups consisted of 7 low back pain patients and 21 healthy, pain free individuals. Blood 
samples were taken both during attack/pain period and attack free/pain free period. Peripheral 
blood mononuclear cell samples were analyzed using ELISpot assay and serum samples were 
analyzed using multiplex ELISA assay. Frequencies of cytokine secreting cells and blood 
cytokine levels were determined, and levels of cytokine production were compared within and 
between groups. 
 
Results: A higher frequency of TNF-α secreting cells than IL-10 secreting cells was observed 
in migraineurs. Lower MCP-1 and IL-10 levels and higher TNF-α levels were observed in 
both migraineurs and low back pain patients compared to healthy, pain free controls.  
 
Conclusions: No cytokines were revealed as possible biomarkers for migraine. A possible 
upregulation of TNF-α and downregulation of MCP-1 and IL-10 may be of relevance, if not 
specifically for migraine, at least for pain in general. The results obtained from the ELISpot 
assay and the ELISA assay were not identical. The two methods provide information about 
cytokine production from different cell sources. Further investigation of cytokine production 
and comparison of the two assays are needed. 
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1. Introduction 
 
1.1 Burden and prevalence of headache 
Headache disorders are considered to be among the most common disorders of the nervous 
system and in accordance with the World Health Organization‘s (WHO) ranking of causes of 
disability, headache is among the ten most disabling disorders for both sexes (1). Chronic or 
recurring headaches impose a physical, mental and economic burden on sufferers and affect 
their quality of life. It may also damage family and social life and employment (2). Headache 
sufferers may have several co-morbidities such as increased incident of depression, anxiety, 
hypertension and stroke (3). Headache disorders are not only a burden for the sufferers itself, 
it also affect the people around them and it is becoming a large economic cost for the society 
(2). A review, written as a preparation for the Eurolight project, estimate that migraine alone 
costs all of Europe 27 billion euro a year, and other headaches probably as much (2).  
 
Headaches are prevalent in both sexes, but usually predominates in women (4). For cluster 
headache it is the opposite (5). In 1995-1997 Sjaastad et al. (6) carried out an epidemiological 
study of headache in Vågå commune, a commune in the mountainous region of southern 
Norway. A total of 1838 (88,6%) of the available 18-65-year-old inhabitants were interviewed 
face-to-face, diagnosed following the criteria of the International Headache Society (IHS) and 
examined personally by Sjaastad (6). Regarding migraine with aura the prevalence was found 
to be 9.7% with a sex ratio (F/M) of 1.70 (7). The prevalence of migraine without aura was 
found to be 31% with a sex ratio of 1.69 (8). For tension-type headache a prevalence of 34% 
was found, with a sex ratio of 1.58 (9). A search was also made for cluster headache and the 
prevalence was found to be 0.33%, with a sex ratio of 0.20 (5). 
In 1989 a similar epidemiological study of headache was carried out in Glostrup, Denmark 
(10). A total of 740 (75.9%) of the ―invited‖, participated and got examined and diagnosed 
following the IHS criteria at the Copenhagen County Hospital in Glostrup (10). The lifetime 
prevalence of migraine was 16% with a sex ratio of  about 3, and for tension-type headache it 
was 78% and the sex ratio 1.25 (10). They only found one case of cluster headache (10). 
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1.2 Migraine 
Migraine is an episodic headache disorder usually divided into two major sub-types, migraine 
without aura (common migraine) and migraine with aura (classical migraine) (11). Clinical 
features of migraine are summarised inTable 1. Following the International Classification of 
Headache Disorders (ICHD; criteria of IHS) (12) both migraineurs with aura and those 
without aura must have had at least five attacks lasting 4-72 hours, with two or more of these 
criteria: unilateral location, pulsating quality, moderate or severe pain intensity and/or 
aggravation by routine physical activity (e.g. walking or climbing stairs). During headache 
they must have had at least one of the following: nausea and/or vomiting, photophobia and 
phonophobia. Migraine with aura include recurrent attacks of reversible focal neurological 
symptoms (the aura phase) that usually develop gradually over 5-20 minutes and last for less 
than 60 minutes. The aura phase often appear as visual disturbances such as fortification 
spectra, flickering lights, zigzag patterns and scotomas (11, 12) (see figure on the front cover). 
Aura can also appear as sensory and/or speech disturbances (12). The pain may be felt deeply 
behind the eye, but more commonly in the frontotemporal region. The pain may also radiate 
backward to the occiput and upper neck (11) (Figure 1). A migraine attack is said to be 
divided into several phases, the premonitory phase being the first, followed by an aura phase 
(in migraine with aura), a headache phase and then a resolution phase. During 1 to 24 hours 
preceding the actual headache migraineurs can experience changes in mood, alertness and 
appetite. These changes can include being irritable, depressed, elated, drowsy or thirsty, or 
even special food cravings. This period is called the premonitory phase. After the headache 
phase has passed, a feeling of exhaustion and lethargy may remain for a day or two. The 
mood can also remain changed under this phase of resolution (11, 12).  
 
 Figure 1: Pain location – Migraine 
The pain during a migraine attack appear unilateral and most commonly in the 
frontotemporal region. It may also appear behind the eye and may radiate 
backward to the occiput and neck. Here illustrated as red areas. 
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1.2.1 Migraine pathophysiology 
Pathophysiological features of migraine are summarised in Table 2. 
  Genetic factors 
Even though the cause of migraine still is uncertain, it is believed that there is a genetic 
predisposition for the development of migraine. Several studies clarifies a family history of 
migraine (most common on the mother‘s side) (13). Anttila et al. claim to have found the first 
genetic risk factor for migraine , and a hypothesis is that this ‗genetic risk factor‘ may be 
involved in regulation of glutamate (14). It is also known that the rare form of migraine, 
called familial hemiplegic migraine, may be caused by mutations in one of the voltage-gated 
calcium channel types (15). 
  Glutamate 
Several studies have documented elevated blood glutamate level in migraineurs between 
attacks and a further increase during attacks (15). It should be mentioned that these findings 
seem to be stronger in migraineurs with aura than without. Different glutamate receptors have 
been identified in the trigeminal nucleus caudalis (TNC) of the rat and ionotropic receptor 
channel blockers seem to be able to block trigeminovascular nociceptive transmission in the 
trigeminocervical nucleus (TCC). Kainate receptor activation seems important for 
trigeminocervical transmission after activation of afferents of the dural vasculature, and also 
dural afferent stimulation after local dural vessel changes (16).  
  Magnesium deficiency 
Magnesium ion is known to gate and block the NMDA glutamate receptor, and therefore play 
a role in glutamate regulation. The intracellular magnesium ion concentration has been found 
to be lowered during migraine headache (15). This may indicate a decreased inhibition of 
glutamate flow through these channels and may be fundamental to an increased cerebral 
NMDA receptor activity. 
  Dysfunctional monoaminergic transmission- dopamine and serotonin 
The symptoms of the premonitory phase probably arise in the hypothalamus and can be a 
result of dysfunctional monoaminergic transmission (15). Activation of periaqueductal gray 
region (PAG), nucleus raphe dorsalis and locus coeruleus (LC) during migraine is consistent 
with an aminergic dysmodulation in the brainstem (Figure 2).  
Migraineurs seem to have both serotonin (5-HT) and dopamine (DA) metabolism 
disturbances (11, 15). A review article by Peroutka et al. highlights some interesting findings 
of activation of dopaminergic receptors in migraine (17). Treatment with low doses of the DA 
agonist, apomorphine, may induce yawning to a higher extent in migraineurs than in healthy 
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controls. Even higher doses of dopaminergic agonists in animals and humans may induce 
other premonitory symptoms like irritability, mood fluctuations and sleep disturbances. 
Treatment with dopaminergic antagonists may reduce migraine-associated nausea and 
vomiting. These findings suggest a dopamine deficiency in migraine (15, 17).  
The 5-HT2 antagonist, pizotyline, may cause euphoria, drowsiness and craving to eat sweet 
foods, which represent some of the already mentioned premonitory symptoms (11). Injection 
of reserpine, which depletes the 5-HT depot, have been shown to induce migraine like 
headaches (15). Serotonine content of blood platelets decrease at the onset of migraine 
headache and at the same time the urinary secretion of the 5-HT metabolite, 5-IHAA, increase 
(15). This discharge of platelet serotonine is thought to reflect depletion of serotonine at 
central synapses, probably in raphe-cortical pathways, and may play a role in inducing 
migraine headache (15, 18). Different 5-HT receptors that may play a role in migraine 
headache are 5-HT1 and 5-HT2 sub-types. 5-HT1B, 5-HT1D and 5-HT1F receptors are found in 
the trigeminal system and are thought to have anti-migraine function when activated (15, 16, 
19). 5-HT1F  receptors are found in the trigeminal nucleus (TN) and the trigeminal ganglion 
(TG) and 5-HT1D receptors are co-localized with calcitonin gene-related peptide (CGRP) on 
fibres in the trigeminal tract (15, 16).  5-HT1B and 5-HT1D agonists (triptans) have shown to 
be effective anti-migraine medications (19). Possibly by mediating vasoactive constriction of 
dilated cranial vessels and inhibiting vasoactive peptide release in the dura, and thereby 
neurogenic inflammation. Possibly by inhibiting central pain impulses in the TCC, and also 
affecting descending impulses from PAG. On the other hand, activation of 5-HT2A receptors 
on unmyelinated sensory nerve fibres causes pain. 5-HT2A antagonists and medications which 
downregulate serotonin synthesis in nucleus raphe seem to have anti-migraine effects (19).  
The trigeminovascular system – component of migraine pathophysiology? 
Nervus Trigeminus is the facial sensory neuron and goes from pons to the trigeminal ganglion 
(TG), where it divides into three branches: nervus opthalmicus, nervus maxillaris and nervus 
mandibularis (20). The trigeminovascular system (TGVS) compose of neurons within the 
trigeminal ganglion, their peripheral projections to the meningeal and cerebral vessels, and 
their second-order neurons in the trigeminal nucleus caudalis (TNC) in the brainstem (21). It 
is also speculated that the trigeminal nucleus extend beyond the traditional nucleus caudalis to 
the dorsal horn at the C1 and C2 levels. The entire group of cells is then called the 
trigeminocervical complex (TCC) (15). For illustration see Figure 2. 
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Figure 2: The Trigeminovascular system 
This figure illustrates the Trigeminovascular System (TGVS); the Trigeminal Ganglion with its three nerve 
branches and its connections to different nuclei in the brain stem, to the meningeal vessels and other brain areas. 
1. Thalamus. 2. Hypothalamus. 3. Trigeminal ganglion, TG. 4. Periaqueductal gray region, PAG. 5. Locus 
coeruleus, LC. 6. Superior salivatory nucleus, SSN. 7. The forth ventricle. 8. Greater superficial petrosal nerve, 
GSP. 9. Sphenopalatine ganglion, SPG. 10. Trigeminal nucleus caudalis, TNC. 11. Trigeminocervical complex, 
TCC. 12. C1 and C2 level of the cervical spine. 13. Dural vessels. 14. Pial vessels. 
 
 
The trigeminovascular theory concerns the large cerebral vessels, the pial and dural vessels 
and the large venous sinuses.  It also concern the nociceptive afferent fibres (C—fibres and 
Aδ-fibres) from the ophthalmic division of the trigeminal ganglion, which surrounds the 
mentioned structures, and their second-order neurons in the brainstem (15, 16), see Figure 2. 
It is believed  that the afferent fibres surrounding the cerebral and meningeal vasculature get 
activated and sensitized (peripheral sensitization) during migraine attacks (22). Activation of 
these primary afferents leads to activation and sensitization of second-order afferents in the 
TCC (central sensitization) and impulses are carried to brain structures involved in pain 
perception, including thalamus and PAG (15, 22). PAG send both ascending projections to 
thalamus and descending projections to the synapse between primary and second-order 
afferents in the dorsal horn (where it modulate nociceptive afferent information) (21). From 
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thalamus the nociceptive impulses goes to the somatosensory cortex, gyrus cinguli and insula 
(19). 
  Calcitonin gene-related peptide 
Stimulation of the trigeminal ganglion has shown to lead to a rise in cranial venous levels of 
calcitonin gene-related peptide (CGRP) and substans P (SP) (23). During migraine, CGRP, 
but not SP, is elevated in the external jugular vein blood (15, 16, 21).  CGRP is a vasoactive 
neuropeptide synthesized in dorsal root ganglion neurons and is released from peripheral 
nerve endings in the brainstem and in the meninges (22, 24). As mentioned under section 
―Dysfunctional monoaminergic transmission- dopamine and serotonin” 5-HT1D receptors are 
co-localized with CGRP on fibres in the trigeminal tract. It is therefore possible that 5-HT in 
some way is involved in the release of vasoactive substances, among them CGRP (15). 
Released CGRP from the trigeminal ganglion produce vasodilation of the meningeal vessels 
and also neurogenic inflammation, as a result of proinflammatory substance secretion in the 
dura by activated mast cells and other local mononuclear cells (19, 22).  
  Neurogenic inflammation 
Neurogenic inflammation results from activation of primary sensory neurons and their release 
of inflammatory mediators such as SP and CGRP (25). CGRP receptors relevant to possible 
neurogenic inflammation in migraineurs, is found in dural mast cells and other mononuclear 
cells, in the trigeminal ganglion, in second order sensory neurons within the trigeminal 
nucleus and in arterial smooth muscle cells. Activation of CGRP receptors in arterial smooth 
muscle cells leads to vasodilation of cerebral and extracerebral arteries (26). Activation of 
CGRP receptors in dural mast cells result in the release of cytokines and other inflammatory 
agents (eg. IL-6, TNF-α and NO) (27). In the trigeminal ganglion, CGRP increases its own 
synthesis and stimulates release of both nitric oxide (NO) and inflammatory cytokines (eg. IL-
6, IL-10, IL-1β) from glial cells, but it also seem to decrease the levels of some cytokines (e.g. 
TNF-α and MCP-1) (23). It is suggested that elevated neuronal CGRP receptors in the 
trigeminal ganglia may sensitize the trigeminal ganglia when activated by CGRP. That the 
increased CGRP synthesis and following neurogenic inflammation possibly may promote, 
sustain and intensify the nociceptive activity during migraine by mediating peripheral 
sensitization (23, 26).  
For a short introduction to inflammation in general and some inflammatory factors, see 
appendix A and Table 9.
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Triggers 
Environmental influences are also thought to be involved in determining the susceptibility to 
migraine. Such environmental influences may be ―triggers‖ like stress, too much or too little 
sleep, food,  hormones and even afferent stimulation like glare, flickering light, noise and 
smells  (13, 28).  
  Pathophysiology of aura 
The origin of visual aura symptoms is the visual cortex and not the retina (11). It is thought 
that the migraineous aura may be a result of  a phenomenon called cortical spreading 
depression (CSD), where waves of depolarization spread from the occipital lobe and forward 
over the cortex, at a speed of 2-3 mm/min, immediately followed by prolonged nerve cell 
depression (15, 29). A brief excitation followed by the depression is thought to be the 
neurophysiological basis of the sensory symptoms experienced during migraineous aura, and 
may be a result of enhanced activity in raphe-cortical pathways (29). CSD may be triggered 
by glutamate, especially by NMDA receptor agonists (29). It may also be triggered by 
descending afferents from the cerebral cortex (activated by emotion or stress), from thalamus 
(activated by excessive afferent stimulation such as glare, flickering lights and/or sound) or 
from hypothalamus (as a response to changes of the body‘s internal environment) (15). 
Studies of acute migraine attacks have revealed regional cerebral blood flow (rCBF) 
reduction, which spread following the cortical surface, from the posterior to the parietal and 
temporal lobes, at the beginning of the attack (29). The aura symptoms seem to appear during 
the early phase of the spreading oligemia and cease while the hypoperfusion continue to 
spread and the headache develops (29). The spreading oligemia lasts for several hours and is 
then followed by a delayed hyperemia. It does not seem likely that the vascular changes 
during CSD causes the migraine headache, because the headache phase usually begins while 
the cerebral blood flow still is diminished and CSD is not associated with migraine without 
aura (15). It is more likely that these changes may be secondary to neural changes in the 
brainstem. It is demonstrated that activation of the trigeminal nerve can mediate cerebral, 
dural and extracranial blood flow to increase, either by directly release of vasodilator peptides 
or via parasympathetic outflow trough the GSP nerve (Figure 2). Stimulation of LC can 
induce both cerebral vasoconstriction and extracranial vasodilation, and the nucleus raphe 
dorsalis can dilate both circulations. The vascular changes may possibly then aggravate the 
headache by further stimulating the vascular afferents (15).  
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1.3 Tension-type headache 
Patients with tension-type headache (TTH) may have a headache of  30 minutes duration only 
recurring every few months, to a continuous, unremitting ache present ―all day and every day‖ 
(30). The headache develops during or after stress (30). Following ICHD, both episodic and 
chronic TTH must have at least two of the following features: bilateral location, a pressing or 
tight (non-pulsating) quality, mild or moderate intensity and/or not aggravated by physical 
activity (12). For pain location, see Figure 3. The headache is not accompanied by nausea and 
vomiting like migraine, but photophobia or phonophobia may be present (12). The definition 
chronic headache is when the headache recurs 15 or more days per month (31). Clinical 
features of TTH are summarised inTable 1. 
 
 
 
 
1.3.1 Tension-type headache pathophysiology  
The ethology behind TTH still seems to be unclear, but it is thought that psychological factors 
like stress, depression and anxiety may be risk factors for the development (30) (Table 2). As 
for genetic factors, a Danish family study done on patients with chronic TTH show an 
increased risk among first- and second-degree relatives (32). Another Danish study done on a 
population of twins with episodic TTH conclude that the primary cause is environmental, not 
genetic (33). Stress and anxiety may contribute to increased excitability in central nociceptive 
pathways as a result of an dysfunctional limbic control of the descending (inhibitory) pain 
control system (34). It also seem that excessive contraction of neck, forehead and jaw 
muscles, in addition to a lowered pain threshold in pericranial sites (frontal, temporal and 
Figure 3: Pain location – Tension-type headache 
The pain during a TTH attack appear as a bilateral, pressing or tight bond around 
the head and neck. Here illustrated as red areas. 
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occipital region), which indicate a central deficit of pain control by the brain‘s endogenous 
pain-control system, is of great importance (30). Some studies, summarized by Ashina et al. 
2005, indicate presence of sensitization at the level of the spinal dorsal horn and the 
trigeminal nucleus (central sensitization) in patients with chronic TTH, but not in episodic 
TTH (34). It is suggested that sustained muscle activity may be sufficient to induce peripheral 
sensitization of muscular nociceptors in patients with TTH (34). One hypothesis, which has 
been challenged, is that release of inflammatory mediators from muscle afferents induces the 
peripheral sensitization (34, 35). According to Lance et al. 2005 it does not exist any evidence 
that sustained vasoconstriction may cause tension-type headache nor aggravate the headache 
like it possible may for migraine headache (30). In contrast with migraine, plasma levels of 
CGRP and glutamate have been reported to be normal in patients with TTH (34). 
 
1.4 Cluster headache 
Cluster headache is defined as a severe piercing and strictly unilateral head or facial pain (36). 
The pain has a tendency to appear in bouts, usually recurring from once every other day to 8 
times a day for a period of weeks or months, separated by intervals of complete freedom for 
months or even years (12, 36). The attacks usually appear at a precise time of day or night 
(36). Following ICHD, a patient with cluster headache must have at least 5 attacks fulfilling 
these criteria: severe or very severe unilateral orbital, supraorbital, and/or temporal pain, 
lasting 15-180 minutes (12). The headache must also be accompanied by at least one of the 
following: ipsilateral conjunctival injection and/or lacrimation, ipsilateral nasal congestion 
and/or rhinorrhoea, ipsilateral eyelid oedema, ipsilateral forehead and facial sweating, 
ipsilateral miosis and/or ptosis, and/or a sense of restlessness or agitation (12). Contrary to 
migraine most of the cluster headache sufferers are men and the pain may be relieved by 
pacing up and down (36). See Figure 4 for pain location and Table 1for clinical features of 
cluster headache. 
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1.4.1 Cluster headache pathophysiology 
There may be a genetic predisposition for the development of cluster headache, but more 
research is needed on this topic (37). Cluster headache pathophysiology is believed to consist 
of three major features: 1. Episodic pattern of the attacks; 2. Cranial autonomic features; and 
3. Trigeminal distribution of the pain (36). Lance and Goadsby (2005) give us a review over 
articles and their general conclusion on this topic (pathophysiological features of cluster 
headache are summarised in Table 2). The main conclusions is that the ipsilateral 
hypothalamic gray matter is likely to be the primary driving area for cluster headache and that 
the pain and the autonomic phenomena may be mediated by suddenly discharge of central 
trigeminal, parasympathetic and sympathetic pathways (36). The daily rhythm of the attacks, 
activation in the ipsilateral hypothalamus during attacks and an increase in hypothalamic gray 
matter in patients with cluster headache suggest the involvement of the hypothalamus and the 
suprachiasmatic nucleus (SCN, which control the circadian rhythm) (36).  Hormonal changes 
such as lowering levels of melatonin and testosterone, and rising levels of cortisol, prolactin, 
platelet serotonin and blood histamine are also indicators of hypothalamus involvement in 
cluster headache (36). Several aspects indicate a postganglionic sympathetic lesion and a 
resulting denervation super sensitivity of receptors in patients with cluster headache (36). 
Examples are: 1. Partial Horner‘s syndrome, like ptosis and miosis. 2. Deficient pupillary 
dilation in response to tyramine (releases noradrenalin (NA) from nerve terminals). 3. 
Excessive pupil dilation in response to phenylephrine (sympathomimetic agent). 4. Lack of 
Figure 4: Pain location – Cluster headache 
The pain during a cluster headache attack appear unilateral and in the orbital, 
supraorbital, and/or temporal region. The pain may also spread back to the neck. 
Here illustrated as red areas. 
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sweating on the medial aspect of the forehead (mediated by sympathetic fibers derived from 
the internal carotid artery. All are ipsilateral to the affected side. 
The partial Horner‘s syndrome may be explained by edema of the wall of the internal carotid 
artery comprising postganglionic sympathetic neurons in the perivascular plexus (36). It has 
been demonstrated narrowing of the lumen of the internal carotid artery, just beyond its entry 
to the skull, at the height of an attack of cluster headache and the effect persisted after the pain 
had ceased. At the same time the ophthalmic artery was dilated, which suggest that  the 
distension of the arterial wall may be caused by vasodilator peptides released from the 
internal carotid ganglion cells, activated by discharge along the GSP nerve (Figure 2), causing 
lacrimation and  conjunctival, nasal and cutaneous vasodilation (36). Vasoactive intestinal 
peptide (VIP), a marker of cranial parasympathetic activation, is elevated during attacks (36). 
Other disorders involving the internal carotid  artery are characterized by pain localized to the 
eye, which also is the case for cluster headache (36). An edema of the wall of the internal 
carotid artery may be a plausible cause of the partial Horner‘s syndrome, though maybe not of 
the pain itself since the effect observed by Ekbom and Greitz (1970) persisted after the pain 
had ceased (36). The ophthalmic division of the trigeminal system dilates the internal carotid 
artery during trigeminal pain (36). The vasodilation observed during cluster headache may 
therefore be a secondary phenomenon, a vasodilator reflex mediated by the trigeminal nerve 
as the afferent limb and  the GSP nerve as the efferent one, which also may be the case for 
migraine (36). Cranial levels of CGRP, a marker for trigeminal activation, are elevated during 
cluster attacks (36). Findings that compression of the upper cervical spine, at the level of C1 
and C2, causes episodic pain with lacrimation and redness of the eye suggest that afferents in 
upper cervical roots also may play a part in the pain generation during cluster headache 
attacks (36).  
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Table 1: Clinical features of primary headaches 
 
 
 Migraine Cluster headache Tension-type headache 
    
Genetic background 
 
Yes 
 
Unknown 
 
Yes/No 
(chronic/ episodic) 
 
Sex ratio (F/M) 
 
1,70 
 
0,20 
 
1,58 
 
Location 
 
Normally unilateral, 
frontotemporal 
 
Unilateral, orbital and/or 
temporal 
 
Bilateral (like a bond around 
the head) 
 
Quality 
 
Pulsating 
 
Piercing 
 
Pressing or tight (non-
pulsating) 
 
Pain intensity 
 
Moderate or severe 
 
Severe or very severe 
 
Mild or moderate 
 
Precipitating/risk 
factors 
 
Stress, unregular sleep, 
food, hormones, glare, 
flickering lights, noise, 
smells 
 
Alcohol 
 
Stress, depression, anxiety, 
excessive muscle contraction 
in neck, forehead and jaw 
 
Frequency 
 
From 1 attack in a lifetime 
to 1 attack almost every 
day 
 
Bouts of 1 attack every 
other day to 8 attacks a 
day 
 
From 1 attack every few 
months to almost every day 
 
Duration 
 
4-72 hours/attack 
 
15-180 min/attack 
 
30 min/attack to a continuous 
headache 
 
Symptoms 
accompanying 
attack 
 
Nausea/vomiting, 
photophobia, 
phonophobia 
 
Conjunctival injection, 
lacrimation, nasal 
congestion, rhinorrhoea, 
eyelid oedema, forehead 
and facial swetting, 
miosis, ptosis 
 
 
Aura/visual 
disturbances 
 
~ 10% 
 
No 
 
No 
 
Physical activity 
 
Aggravate pain 
 
Relieve pain 
 
Do not aggravate pain 
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Table 2: Patophysiological features of primary headaches 
 
 
 Migraine Cluster headache  Tension-type headache 
    
Hypothalamus involvement 
 
Yes 
 
Yes 
 
No 
 
Involvement of upper cervical 
spine (C1 and C2 level) 
 
Possible 
 
Possible 
 
Yes 
 
Vascular component 
 
Yes 
 
Yes 
 
No 
 
Parasympathetic involvement 
 
Probably  
 
Yes 
 
No 
 
Sympathetic involvement 
 
No 
 
Yes 
 
No 
 
Central sensitization 
 
Yes 
 
No 
 
Yes 
 
Peripheral sensitization 
 
Yes 
 
No 
 
Possible 
 
Hormonal imbalance 
 
↓ Dopamine 
 
↓ Melatonine and 
Testosterone  
 
↑ Cortisol, Prolactin 
and Histamine 
 
No 
 
Serotonine 
 
↓ 
 
↑ 
 
Normal 
 
CGRP 
 
↑ 
 
↑ 
 
Normal 
 
Glutamate 
 
↑ 
 
Normal 
 
Normal 
 
Inflammatory component 
 
Probably 
 
Probably 
 
Unknown 
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1.5 Headache, inflammation and cytokines 
Today there are no biomarkers for differentiation of headache syndromes. Diagnosis is made 
by clinical examination, excluding organic causes of headache and following clinical criteria. 
Basing the diagnosis on just clinical symptoms can make it difficult to distinguish between 
the different headache syndromes, specially between migraine and TTH. If it is possible to 
find specific biomarkers for the different headache syndromes it may help distinguish them 
from each other and hence, make it easier to give a proper diagnosis and targeted treatment.  
 
There are reasons to believe that there is an inflammatory response during migraine and 
cluster headache attacks. Both of them are associated with blood serotonin and CGRP 
changes and both of them have a vascular component. On the other hand there are no reasons 
to expect an inflammatory response of significance during tension-type headache attacks. This 
type of headache is believed to only consist of a neurologic component and is not associated 
with blood serotonin and CGRP changes. See Table 2 for some of the pathophysiological 
features of the three mentioned headache syndromes. 
 
Cytokines possess multiple biologic activities that promote cell-cell interaction and play an 
important role in immunology, pain and inflammation (24) (see Table 9, appendix A). Several 
studies have linked different cytokines to migraine pathogenesis (Table 3), but the results 
have been conflicting. In addition, other authors indicate a possible contribution of TNF-α and 
IL-1β gene polymorphism to migraine headache (38).  
 
Cytokines are of interest for this study as possible biomarkers that can help differentiate the 
three mentioned headache syndromes. Studies have shown that some cytokines, such as IL-6, 
TNF-α and IL-1, induce dose-dependent hyperalgesia, and may therefore be considered as 
pain mediators in neurogenic inflammation (39, 40). IL-10 has been shown to inhibit 
hyperalgesic responses to TNF-α, IL-1β and IL-6, whereas IL-4 only to TNF-α (41, 42).  
 
It is of interest to compare samples from the different headache groups with low back pain 
patients and healthy, pain free individuals. Lumbago, or low back pain, defined as back pain 
located in the lumbar region (between the bottom of the ribcage and above the legs), is 
considered to be a very painful condition (43). By comparing samples from headache and low 
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back pain patients, it may be possible to define cytokines as an inflammatory response to pain 
in general or to the different painful conditions. 
 
Table 3: Cytokines and migraine 
 
This table lists some of the migraine studies that have covered the topic ―cytokines and migraine‖. Control 
subjects are healthy, pain free individuals, if not otherwise noted. *Control subjects are patients with TTH, 
**During attack vs. outside attack.  (24, 44-49) 
 
Authors Cytokines Headache syndrome Samples 
    
Munno et al. 1998 
 
Elevated IL-4 and IL-5, no 
significant difference of IL-10 and 
IFN-γ 
 
Migraine without aura 
 
Plasma, outside 
attack 
 
Fidan et al. 2006 
 
Elevated IL-10 and IL-6, no 
significant difference of IL-1β, IL-
2, TNF-α and IFN-γ 
 
Migraine with and without 
aura 
 
Serum, during 
attack 
 
Sarchielli et al. 2006 
 
Elevated TNF-α, IL-6 and IL-1β, 
decreased IL-4 
 
Migraine without aura 
 
Plasma, during 
attack 
 
Bockowski et al. 2009 
 
No significant difference, but a 
tendency of elevated IL-1α and 
TNF-α* 
 
Migraine with and without 
aura (children) 
 
Plasma, outside 
attack 
 
Perini et al. 2005 
 
Elevated IL-10, TNF-α and IL-1β, 
no significant difference of IL-6, 
IL-4 and IL-2** 
 
Migraine with and without 
aura 
 
Plasma, during 
and outside 
attack 
 
Munno et al. 2001 
 
Elevated IL-10, undetectable levels 
of IL-4, IL-5 and IFN-γ 
 
Migraine without aura 
 
Plasma, during 
attack 
 
Empl et al. 2003 
 
No significant difference of TNF-α 
and IL-6 
 
Migraine with and without 
aura 
 
Serum, during 
attack 
 
 
 
1.6 Enzyme-linked immunoassay techniques  
For studying cytokines, enzyme-linked immunoassay techniques, such as ELIspot assay and 
ELISA multiplex cytokine assay, will be used. Both assays are solid phase protein assays 
using membrane or beads as the solid support. They are based on enzyme-linked 
immunoassay techniques using primary protein-specific capture antibodies that bind to the 
protein of interest (cytokines in our case) and secondary biotinylated detector antibodies, 
which also bind to the protein of interest, making a complex. Streptavidin, conjugated to an 
enzyme or a fluorescent protein, which bind to the biotinylated detector antibody, is also used 
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for ELISpot and multiplex ELISA respectively (Figure 5 A.). A substrate solution for 
development is also needed using the ELISpot assay (Figure 5 B.). A development step is not 
needed for ELISA; the fluorophore quantity is measured directly. (50, 51). 
 
A. B. C.  
Figure 5: Enzyme-linked immunoassay techniques 
A. The ELISpot assay uses a membrane as the solid support. Bound protein-specific capture antibodies (green Y) 
make a complex with cytokines (red), biotinylated detector antibodies (orange Y + B) and enzyme conjugated 
Streptavidine (circle with red Cs on). B. For development, a substrate solution is added (S). The enzyme convert 
the substrate to a colored precipitate (dark blue). C. Dark spots emerge on the membrane. Each spot represent a 
cytokine secreting cell.  
 
 
1.7 Objectives 
This thesis is considered to be a pilot study and the objectives are: 
1. Identify cytokines as possible specific biomarkers for migraine, cluster headache and 
tension-type headache 
2. Define cytokine secretion as possible inflammatory response to pain  
3. Evaluate the use of ELISA assay and ELISpot assay for this purpose 
4. Evaluate strengths and flaws of this pilot study and suggest improvements for future 
studies 
 
We do hope this study, and further studies on this topic, will contribute to increased 
understanding and knowledge about the physiological processes involved in the development 
of headache, and valuable knowledge about headache that later can turn out to be useful 
regarding treatment
2. Methods and materials 
17 
 
2. Methods and materials 
 
2.1 Study preparations 
 
2.1.1 Applications 
This master‘s thesis project in Human Physiology was approved by the Program Committee, 
Institute of Biomedicine, Faculty of Medicine and Odontology, University of Bergen autum 
2009. Project application was accepted by the Regional Committee of Ethics (REK). A 
research protocol describing the project title, introduction, aims, patient selection and methods 
was included.  
 
2.1.2 Patient selection 
The original plan was to include 20 patients with migraine, cluster headache and tension-type 
headache respectively, and two control groups consisting of 20 low back pain patients and 20 
healthy, pain free individuals. 
All patients with a severe acute headache or low back pain, hospitalized at the Department of 
Neurology, Haukeland University Hospital, during February 2010 to February 2011, were 
asked to participate.  
Due to the limited timespan of the study, only 15 patients with headache and 7 with low back 
pain agreed to participate and gave their written consents.  
21 male divers at the age of 20-25 from the Norwegian Navy, already participating in another 
ongoing study at Haukeland University Hospital, were included in the healthy, pain free 
group. The group was not age and gender matched. Previous studies have not found any 
correlation between age, gender and cytokine production in migraineurs (24, 48, 52).  
 
2.1.3 Examination, diagnose and exclusion 
Clinical examination and diagnosis were made by neurologists at the Department of 
Neurology, Haukeland University Hospital. Headache patients were personally interviewed 
about the on-going headache attack and their case history using questionnaires based on the 
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diagnostic criteria from the International Classification of Headache Disorders (ICHD), 2
nd
 
edition (12) (for questionnaires see appendix B and C). Diagnoses were confirmed and 
clinical data, such as history of other diseases and the use of medications, were known using 
these questionnaires. Patients were excluded from the study if they had other inflammatory 
diseases, if they had low back pain and headache, combined headache, or if they had other 
underlying organic causes of headache than migraine, cluster headache and tension type 
headache. A different questionnaire was used for the low back pain patients to rule out any 
history of headache or other inflammatory diseases. Medical screening of the healthy pain 
free individuals was already done by the Norwegian Navy prior to the study and 
questionnaires about their medical condition were filled out.  There were no reasons not to 
include them in the healthy pain free control group. 
Of the 15 headache patients, 11 were diagnosed with migraine. Patients excluded from the 
study were two with tension type headache, one with combined headache (tension type 
headache + migraine) and one with brain hemorrhage. No patients with cluster headache were 
hospitalized during the period of patient recruitment. Some of the clinical data regarding the 
migraine and low back pain patients are listed in Table 4. 
 
Table 4: Clinical data – migraineurs and low back pain patients 
This table lists some of the clinical data from the questionnaires. *Medications taken were triptans, opioids and 
NSAIDs. 
 
Diagnosis N  Sex 
(F/M) 
Age,  
min – max 
(median) 
History of 
headache 
(%) 
Family 
history of 
headache 
N (%) 
Frequency of 
headache attacks 
(days per month) 
Medications* 
taken prior 
blood sampling 
N (%) 
        
Migraine 11 10/1 16-66 
(43) 
100 7 (64) 2-15 6 (55) 
        
Low back 
pain 
 
7 5/2 32-58 
(53) 
0 5 (71) 0 7 (100) 
 
 
2.2 Sample preparations 
Blood samples were collected by bioengineers at the Laboratory for Clinical Biochemistry 
and serum was isolated and stored at the Laboratory for Neurological Research, Department 
of Neurology, Haukeland University Hospital, if not otherwise noted. 
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2.2.1 Blood sampling 
Blood samples were collected from patients at different periods of time. The first blood 
samples were collected at the time of hospitalization while patients still were in intense pain. 
The second blood samples were collected 1- 2 months after hospitalization, during a pain free 
period. The patients had been pain free for at least two days. Blood samples from the healthy, 
pain free divers were collected, and serum isolated and stored, prior to this study. The divers 
had not been training or diving, and had no complaints of headache or pain for at least two 
days before sampling. 
 
2.2.2 Serum isolation and storage 
For each patient 2 x serum separator gel tubes (catalog no. 367957,  BD Biosciences, 
Trondheim, Norway) were filled with blood (Table 5). These tubes contain clot activator 
(silica particles that coat the walls) and serum separator gel (53). In order to allow coagulation 
the samples were stored upright at room temperature (20˚C) for 30 minutes. The samples were 
then centrifuged at 3000 rpm for 10 minutes. The serum separator gel isolate serum from 
blood cells by forming a physical barrier between the two during centrifugation (53). After 
centrifugation, serum (the upper layer) was transferred into cryotubes and stored at -80°C 
until analysis. 
 
Table 5: Serum samples 
Serum samples were isolated for all participating patients, but not all of the patients gave blood both during 
attack/pain period and attack free/pain free period. 
 
Group Attack/pain period Attack free/pain free period Both periods 
    
Migraine 1 2 8 
 
Low back pain 
 
3  4 
Healthy, pain free  21  
 
 
2.2.3 Peripheral blood mononuclear cell isolation 
Isolation of peripheral blood mononuclear cells (PBMCs) was performed according to the 
manufacturers description (54).  
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For each patient 3 x cell preparation tubes (CPTs) (catalog no. 362780, Puls AS, Oslo, 
Norway) were filled with blood (Table 6). These tubes contain sodium heparin anticoagulant 
and blood separation media. The blood samples were stored upright at room temperature 
(20˚C) until centrifugation. PBMCs were isolated by centrifugation at 1650 g for 20 minutes 
at 20°C. During centrifugation the gel portion of the media moves and separates PBMCs and 
platelets from the denser blood components below (Figure 6) (54). Blood plasma (upper 
yellow solution) was transferred to a 15 ml centrifuge tube and stored at - 20˚C. PBMCs 
(whitish layer) were transferred to a 15 ml centrifuge tube, washed and cryopreserved at -
80°C. The PBMCs were washed twice with sterile phosphate buffered saline (PBS) (the 
Production Laboratory, Haukeland University Hospital), and centrifuged at 300 g for 10 
minutes at 4°C, to reduce the quantity of platelets present, resulting in a suspension of 
concentrated mononuclear cells (54).  
 
 
 
 
 
 Figure 6: Isolation of peripheral blood mononuclear cells 
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Table 6: PBMC samples 
PBMC samples were only isolated for five migraine patients. One of the patients did not give blood during both 
the attack and the attack free period. 
 
Group Attack/pain period Attack free/pain free period 
   
Migraine 
 
4 5 
 
 
2.2.4 Cryopreservation and storage of PBMCs 
The isolated PBMC samples were transferred to cryotubes and freezing media containing 
90% (900μl) Fetal Bovine Serum (FBS) (catalog no. A15-152, PAA The Cell Culture 
Company, Cölbe, Germany) and 10% (100μl) cryoprotectant, DimethylSulfoxide (DMSO) 
(catalog no. 1.02931.0500, VWR, Oslo, Norway), was added. Addition of freezing media is to 
avoid damage of cells due to lethal ice crystal formation and osmotic injury during freezing 
(55). In order to avoid intracellular freezing, the PBMC samples were gradually brought to 
lower temperatures (~ 1°C/min) by using an alcohol-free cool cell box (catalog no. 479-0492, 
VWR, Oslo, Norway) the first 24 hours at -80˚C (55). The tubes were transferred to a cryobox 
(catalog no. 479-0111, VWR, Oslo, Norway) for further storage (1-2 weeks) at -80˚C.  
 
2.2.5 Thawing of cryopreserved PBMCs 
It is important to thaw cryopreserved PBMC samples rapidly to minimize osmotic variations 
due to slow thawing and also to avoid the toxic effect of DMSO (55). The PBMC samples 
were thawed by adding room tempered cell media (RPMI 1640 supplemented with Glutamine 
(catalog no. 12-702F, Lonza, Walkersville, USA), containing 10 % heat inactivated FBS 
(catalog no. A15-152, PAA The Cell Culture Company, Cölbe, Germany) and 1 % 
Streptomycin Penicillin (S/P) antibiotics (catalog no. P4333, Sigma-Aldrich, Steinheim, 
Germany)). Thawed PBMC samples were transferred to 15 ml centrifuge tubes, washed in 
cell media and centrifuged at 300 g for 15 minutes at 4˚C. After centrifugation, supernatant 
was removed (not entirely to avoid drying out the cells) and the pellet re-suspended in 2 ml 
cell media. Depending on pellet size after isolation, 1.25-10 μl of PBMCs, suspended in cell 
media, was diluted (1:8000 – 1:1000) in 10 ml of filter sterilized CASYton (catalog no. 
05651808001, Roche Applied Science, Oslo, Norway). Viable PBMCs were counted using a 
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CASY cell counter and analyzer (Roche Diagnostics, Oslo, Norway). The rest of the PBMC 
samples were washed once more and the pellet re-suspended in 2 ml cell media. 
 
2.3 Analysis 
In order to look for different inflammatory markers for migraine, the frequency of cytokine 
producing cells and blood cytokine levels were determined by analysing peripheral blood 
mononuclear cell (PBMC) samples and serum samples. Analyses were done by using human 
ELISpot assay kits (catalog no. 3430-2HW-Plus, 3520-2HW-Plus and 3510-2HW-Plus, 
Mabtech, Nacka Strand, Sweden) and human cytokine 25-plex assay kit (catalog no. 
LHC0009, Invitrogen, Paisley, UK). The ELISpot assays were scanned using an automated 
ImmunoScan Plate Reader (CTL-Europe GmbH, Bonn, Germany) and the frequency of 
cytokine producing cells determined by using ImmunoSpot Analysis software (CTL-Europe 
GmbH, Bonn, Germany). The cytokine 25-plex ELISA assay was measured on a Luminex®
 
100™ system (Luminex, Austin, TX) and the cytokine levels determined by using StarStation 
software (Applied Cytometry Systems, Dinnington, Sheffield, UK).  
 
As a ―cytokine fishing expedition‖ all serum samples (Table 5) were analysed using the 
ELISA 25-plex cytokine assay kit. Mean cytokine levels were compared within and between 
the different groups; migraine, low back pain and healthy, pain free. Due to the limited time 
span and the low budget of this study, only samples from five headache patients were 
analysed using the ELISpot assay (Table 4). The frequency of IL-17 and TNF-α secreting 
cells was compared within the group, attack vs. attack free.  
 
2.3.1 ELISpot assay 
ELISpot assays for human interleukin-10 (IL-10), interleukin-17 (IL-17) and tumor necrosis 
factor α (TNF-α) were performed according to the manufacturer‘s descriptions, with minor 
modifications (56-58). Instead of using the PVDF-based membrane plates from the kits, 
MultiScreen HTS HA plates (catalog  no. MSHAN4550, Millipore, Oslo, Norway) were used. 
This was done to avoid the critical activation step needed for the PVDF-based membrane 
plates. A mock experiment was carried out to compare the different plates.  
The assay protocols for the different cytokines were virtually identical, with minor differences 
in recommended cell number per well and use of polyclonal activators for positive assay 
controls. Negative assay controls (wells without coating and wells without cells) were also 
2. Methods and materials 
23 
 
applied for each sample. Layouts (not shown) and all dilutions for the IL-10, IL-17 and TNF-
α assays were made according to the manufacturer‘s descriptions and personal 
recommendations from Gun Kesa, PhD Research Scientist at Mabtech AB (56-58).  
 
DAY 1 - Coating 
100 μL/well of coating antibody solution was added in appropriate wells and incubated 
overnight (14-24 hours) at 4˚C. Coating antibodies were diluted in sterile PBS and 
calculations of volume PBS and antibody needed were done according to equation 1 and 2. 
 
Equation 1: Total volume PBS/media needed for all wells 
Total volume PBS/media needed for all wells = (number of wells) x (μL/well) 
 
Equation 2: Volume antibody/stimulant needed 
 
C1 x V1 = C2 x V2 
C1 = Stock concentration (μg/ml) 
V1 = Volume antibody/stimulant needed (ml) 
C2 = Needed concentration (μg/ml) 
V2 = Total volume PBS/media needed for all wells (ml) 
 
DAY 2 - Plating 
The plates were blocked with 250 μL/well of cell media for 2 hours at 37oC in a 5% CO2 
incubator (Binder, Tuttlingen, Germany). Cell suspensions of different concentrations 
(cells/mL) (Table 7) were made by diluting the isolated PBMC sample in cell media. 
Calculations of volume isolated PBMC sample needed were done according to equation 1, 3 
and 4.  
 
Equation 3: Number cells needed per mL 
 
Needed number cells/mL = Number cells/well x Number wells/mL 
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Equation 4: Total volume isolated PBMC sample needed for all wells 
 
Volume isolated PBMC sample needed (mL) = (total volume needed (mL) * number cells 
needed/mL) / (counted number viable cells/mL) 
 
 
Table 7: Cell suspensions 
Concentration of the different cell suspensions added in each well is expressed as cells/ml. A concentration of 
1x10
6
 cells/ml gives 1x10
5
 cells/well. 
 
 TNF-α (cells/ml) IL-10 (cells/ml) IL-17 (cells/ml) 
    
Non stimulated 2.5 x 10
6
 
1.25 x 10
6 
2.5 x 10
6
 
1.25 x 10
6 
5 x 10
6
 
2.5 x 10
6 
Stimulated 5 x 10
5
 
2.5 x 10
5 
1 x 10
6 
5 x 10
5 
2 x 10
6
 
1 x 10
6 
 
 
After blocking, 100 μl/well of diluted cell suspension (Table 7) was added to the appropriate 
wells. For the positive assay control (stimulated) wells only 50 μl/well of cell suspension, 
double the wanted concentration (cells/mL), was added. Then 50 μl/well of stimulant diluted 
in cell media, double the wanted concentration, was added in the same wells giving a total of 
100 μl/well. For IL-10 and IL-17 a dilution of 1:1000 (1μl/ml) of the polyclonal activator anti-
CD3 mAb was used. For TNF-α, the polyclonal activator phytohemagglutinin (PHA), with a 
concentration of 5 μg/ml, was used. Calculation for the PHA dilution was made according to 
equation 1 and 2. The plates were then incubated overnight (14-24 hours) at 37˚C in a 5% 
CO2 incubator. 
 
DAY 3 - Development 
The plates were washed with sterile PBS followed by 5 washes with PBS containing 0.05% 
Tween 20 (PBS-T). For the last 2 washes the plates were soaked for 2-5 minutes and filtered 
using an Empore™ 96-well Vacuum Manifold (catalog no. 66879-U, Sigma-Aldrich, 
Steinheim, Germany). PBS-T was made by dissolving one PBS tablet (catalog no. 09-9400-
100, Medicago AB, Uppsala, Sweden) per litre sterile water, and adding 0.05% Tween20 
(catalog no. 8.22184.500, VWR, Oslo, Norway).  
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After washing, the plates were incubated for 2 hours at room temperature (20˚C) with 100 
μl/well of detection antibody solution. To avoid non-specific spot formation, due to protein 
aggregates, during development, the detection antibody solution was filtered through a 0,2μm 
filter (catalog no. 514-4126, VWR, Oslo, Norway) (59). The detection antibody solution was 
made by diluting the antibody in PBS containing 0.5% FBS. Calculations of volume detection 
antibody needed were made according to equation 1 and 2.  
After incubation, the plates were washed and 100 μL/well of Streptavidine-HRP diluted in 
PBS-0.5% FBS was added. The plates were incubated for 1 hour at room temperature (20˚C).  
After incubation, the plates were washed and 100 μl/well of the ready-to-use 
tetramethylbenzidine (TMB) substrate solution was added. Development time, time until 
distinct spots emerged, differed for the different cytokines (usually between 10 to 40 
minutes). TNF-α was the fastest to develop.  
The development process was stopped by rinsing the plates under running water. The plates 
were tapped dry on paper in between and rinsing was repeated until no more soap remained. 
The plates were allowed to dry in the dark for 2 days at room temperature (20˚C). 
 
DAY 5 - Counting 
The fifth day, after punching out membranes on clear sealing tape (catalog no. 95.1994 and 
82.1586, Sarstedt, Ski, Norway), membranes were scanned and spots were counted. Each spot 
represented a cytokine secreting cell. To avoid fading after scanning, the membranes were 
covered with aluminium foil and stored at room temperature (20°C) in the dark.  
 
2.3.2 Cytokine 25-plex ELISA assay 
Cytokine 25-plex ELISA assay was performed according to the manufacturer‘s descriptions 
(51). All headache samples and low back pain samples were analyzed in one experiment. The 
healthy pain free samples were analyzed in a separate experiment together with other samples 
from the other ongoing study at Haukeland University Hospital. All standards were run as 
duplicates and samples as singles, allowing 80 samples per plate.  
 
All samples were allowed to thaw and all reagents to warm to room temperature (20°C) for 
approximately 30 minutes. Dilutions were made according to the manufacturer‘s descriptions 
(51). 
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1x working wash solution was prepared by diluting concentrated wash solution with 
deionized water (1:20) and mixed until completely dissolved. To avoid unnecessary clotting 
of wells, assay diluent was centrifuged at 3000 min-1 for 10 min and the pellet (salt 
precipitate) was discarded. One 16-plex and one 14-plex standard vial were reconstituted by 
adding 0.5 mL assay diluent in each vial. The solutions were then combined, making standard 
8 (1:1). Serial dilutions were made by diluting 300 μL of standard 8 in 600 μL assay diluent, 
making standard 7 (1:3). 300 μL of standard 7 was then diluted in additional 600 μL assay 
diluent, making standard 6 (1:9) and so on (making 8 different standard dilutions, with 
standard 1 diluted 1:2187).  
 
All 96 wells were pre-wet by adding 200 μL of working wash solution. The antibody bead 
solution was mixed by gently vortexing and then diluted 1:4 in working wash solution and 
sonicated for 30 sec. Dilution was done to easier distribute the beads more equal in each well.  
 
After each incubation, the solution added was aspirated off from the bottom of the plate by 
using a multiscreen vacuum manifold (catalogue no. MSVMHTS00, Millipore, Oslo, 
Norway), and the beads washed. After each washing step, the bottom of the plate was 
carefully blotted on clean paper towels until completely dry, to avoid leakage when adding 
new solutions. 
 
100 μL of the diluted bead solution was added into each well and washed twice with 200 
μL/well of working wash solution. To protect the beads from light, a black plate cover was 
used. 50 μL/well of incubation buffer was added into each well and 100 μL/well of standard 
dilutions were added into appropriate wells. 50 μL/well of assay diluent, followed by 50 
μL/well of sample, was added to appropriate wells. The plate was then incubated in the dark 
at room temperature (20°C) on an orbital shaker for 2 hours. Lipemic samples (whitish 
colour) were centrifuged at 2000 g for a couple of minutes in a micro-centrifuge (Galaxy 
Mini, 521-2812, VWR, Oslo, Norway) and the lipid layer discarded. Standard dilutions were 
stored at -20°C overnight for the next experiment.  
 
1 mL of 10x biotinylated antibody concentrate was diluted in 10 mL of biotin diluent (1:11). 
After two washing steps, 100 μL/well of the diluted biotinylated anibody solution was added. 
The plate was incubated for 1 hour. 
2. Methods and materials 
27 
 
1 mL of 10x R-Phycoerythrin conjugated Streptavidin (Strep-RPE) concentrate was diluted in 
10 mL Strep-RPE diluent (1:11). After two washing steps, 100 μL/well of the diluted Strep-
RPE was added. The plate was incubated for 30 minutes. 
 
After the last incubation, the beads were washed three times and re-suspended in 100 μL/well 
of working wash solution. The samples were then analysed with a Luminex
®
 100
™
 instrument 
(Luminex, Austin, TX) and the concentration of the samples (pg/mL) were determined from 
the standard curve using StarStation 2.3 software (Applied Cytometry Systems, Dinnington, 
Sheffield, UK). 
 
2.4 Statistics 
Statistical analyses were performed using GraphPad Prism 5 Software, demo version 
(http://www.graphpad.com/demos/).  
Changes in frequency of cytokine secreting cells, during migraine attack and attack free 
periods, were analyzed using the Wilcoxon matched-pairs signed rank test, and between 
cytokine groups (TNF-α, IL-17 and IL-10) using the Kruskal Wallis test. Dunn‘s Multiple 
Comparison test was used as post hoc analysis.  
Cytokine levels in serum were compared, between migraine, low back pain and healthy, pain 
free groups, using the one-way analysis of variance (ANOVA). Changes in cytokine levels, 
during migraine attack and attack free periods, and during low back pain and pain free 
periods, were analyzed with the two-tailed paired Student‘s t-test. The Tukey Multiple 
Comparison test was used as post hoc analysis. Differences were accepted as statistically 
significant at p<0.05. 
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3. Results 
 
3.1 ELISpot assay 
PBMC samples were isolated from five migraine patients (Table 6). The samples were 
analyzed for TNF-α, IL-10 and IL-17 secreting cells using ELISpot assay kits. Results are 
illustrated in Figure 8. Mean frequency of TNF-α and IL-17 secreting cells were compared 
within the migraine group, during attack and attack free periods respectively. 
 
3.1.1 PVDF-based membrane plate vs. HTS HA plate 
Figure 7 shows differences seen comparing the use of HA plate with the use of PVDF-based 
membrane plate. Both plates were coated and plated following the same layout.  
 
The PVDF-based membrane plate developed a much darker background color during 
development (Figure 7A-C) than the HA-plate (Figure 7 D-F). For IL-10 and IL-17 there were 
no big differences in mean cytokine secreting cells for the two plates (Figure 7, B vs. E and C 
vs. F). Even though a big difference in mean TNF-α secreting cells detected was observed for 
the two plates (Figure 7A vs. D), the mean detected using the HA plate was still high (Figure 
7 D). 
 
 
A.     B.     C.  
D.     E.      F.  
 
 
Figure 7: PVDF-based membrane plate vs. HTS HA plate 
A-C. PVDF-based membrane plate. A. TNF-α. B. IL-10. C. IL-17. D-F. HTS HA plate. D. TNF-α. E. IL-10. F. 
IL-17. All figures are marked with their mean cytokine secreting cell number per 100.000 cells. 
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3.1.2 Positive controls  
Results for the positive control wells are listed in Table 8.  
For TNF-α and IL-17, the test system functioned properly for 8 of 9 samples (positive mean). 
For IL-10, the test system functioned properly for 5 of 9 samples (positive mean). 
 
 
Table 8: Positive controls 
Each patient sample was stimulated with a polyclonal activator as a control of the test system‘s functionality. A 
positive mean of cytokine secreting cells per 100.000 cells in the control wells, indicated a functional test 
system.  
 
Patient TNF-α IL-10 IL-17 
p.1 (attack) positive positive positive 
 
p.1 (attack free) positive negative positive 
 
p.6 (attack) positive positive positive 
 
p.6 (attack free) negative negative negative 
 
p.7 (attack) positive positive positive 
 
p.7 (attack free) positive negative positive 
 
p.8 (attack) positive positive positive 
 
p.8 (attack free) positive negative positive 
 
p.9 (attack free) positive positive positive 
 
 
3.1.3 Cytokine secreting cells in migraine patients 
Mean of cytokine secreting cells (unstimulated) per 100.000 cells were calculated for those 
PBMC samples analyzed where the test system functioned properly.   
Results for the migraine patients are presented in Figure 8.  
 
Mean frequency of TNF-α secreting cells were significantly higher than mean frequency of 
IL-17 secreting cells (P= 0.0047). No secreting cells were found for IL-17. No differences 
were found, between migraine attack and attack free periods. There was a high distribution of 
frequencies of TNF-α and IL-10 secreting cells (Figure 8 A). Changes observed, during attack 
compared to attack free period, were not identical. Two of the patient means were elevated 
during attack, while one was decreased (Figure 8 B). 
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Figure 8: Cytokine secreting cells in migraine patients 
The frequency of cytokine secreting cells is expressed as mean secreting cells per 100.000 cells. Each spot 
represent one patient. A. Changes in frequency of cytokine secreting cells, during migraine attack and attack free 
periods, were compared for TNF-α and IL-17 using the Wilcoxon matched-pairs signed rank test. Comparison 
between the different cytokines was done using the Kruskal Wallis test, with Dunn‘s Multiple Comparison test 
as post hoc analysis. Differences were accepted as statistically significant at p<0.05. B. Changes of individual 
mean TNF-α levels, during attack compared to attack free period. Each patient is marked with an individual 
patient number (eg. p.1). 
 
 
3.2 ELISA assay 
Serum samples (Table 5) were analyzed for 25 different cytokines using a 25-plex ELISA 
assay kit. These cytokines were MCP-1, TNF-α, IL-10, IL-1β, IFN-γ, IL-2, IL-4, IL-5, IL-6, 
IL-7, IL-8, IL-12 (p40/p70), IL-13, IL-15, IL-17, IFN-α, IL-1ra, IL-2r, IP-10, MIG, MIP-1α, 
MIP-1β, GM-CSF and RANTES.  Figure 9 to Figure 17 show the results for MCP-1, TNF-α, 
IL-10, IL-1β and IL-17.  Mean cytokine levels (pg/ml) were compared between and within 
groups. 
 
3.2.1 Cytokine levels in migraine and low back pain patients 
MCP-1 result is shown in Figure 9 and Figure 10. 
Mean MCP-1 levels were high (min. 210 pg/ml). A high distribution of results was observed 
within each group (Figure 9). Mean MCP-1 levels were significantly higher (P = 0.0223, one-
way ANOVA) in the healthy, pain free group than in the migraine, attack free group. A 
tendency also observed for all the other patient subgroups. In the migraine group, 5 of 8 of the 
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individual mean MCP-1 levels were decreased during attack (Figure 10 A). 3 of 4 of the 
individual mean levels in the low back pain group were elevated during pain (Figure 10 B). 
 
 
Figure 9: MCP-1 levels 
Individual MCP-1 levels are expressed as mean (pg/ml). Each spot represent the mean (pg/ml) for one patient. 
MCP-1 levels were compared between each group by using one-way ANOVA (P-value is highlighted by capped 
line). The Dunnett's multiple comparison test was used as post hoc analysis.  Differences were accepted as 
statistically significant at p<0.05. The assay sensitivity for MCP-1 (8 pg/ml) is shown with a broken line. 
 
 
 
 
Figure 10: MCP-1 levels in migraineurs and low back pain patients 
Serum MCP-1 level for each patient is expressed as mean (pg/ml). Each spot in each group represent the mean 
(pg/ml) for one patient.  P.1 in A. and in B. is NOT the same patient.  Changes in mean MCP-1 level, A. during 
migraine attack and attack free periods, and B. during low back pain and pain free periods, were analyzed using 
the two-tailed paired Student‘s t-test. Differences were accepted as statistically significant at p<0.05. 
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TNF-α result is shown in Figure 11and Figure 12.  
Interestingly, 33 % of the healthy, pain free individuals had a mean below the assay 
sensitivity (5 pg/ml), while all patients were above this limit (Figure 11). Changes of the 
individual TNF-α levels, during an attack compared to attack free period, were not identical 
(Figure 12 A). This observation was also true for low back pain patients (Figure 12 B).  
 
Figure 11: TNF-a levels 
Serum TNF-α level for each patient is expressed as mean (pg/ml). Each spot represent one patient. TNF-α levels 
were compared between each group using one-way ANOVA. The Tukey multiple comparison test was used as 
post hoc analysis.  Differences were accepted as statistically significant at p<0.05. The assay sensitivity for TNF-
α (5 pg/ml) is shown with a broken line. 
 
 
 
Figure 12: TNF-a levels in migraineurs and low back pain patients 
Serum TNF-α levels for each patient are expressed as mean (pg/ml). Changes of mean TNF-α levels for each 
patient are demonstrated with a line for A. migraine and B. low back pain patients. P.1 in A. and in B. is NOT 
the same patient.  Mean TNF-α levels were compared within each patient group using the two-tailed paired 
Student‘s t-test. Differences were accepted as statistically significant at p<0.05. 
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IL-10 result is shown in Figure 13.  
A tendency of lower mean IL-10 levels in the patient groups than in the healthy, pain free 
group was observed. 52 % of the healthy, pain free individuals had a mean above the assay 
sensitivity (3 pg/ml), while 78 % of all patients (73% of the migraine patients and 86% of the 
low back patients) were below this limit.  
 
 
 
Figure 13: IL-10 levels 
Serum IL-10 level for each patient is expressed as mean (pg/ml). Each spot in each group represent the mean 
(pg/ml) for one patient. IL-10 levels were compared between each group by using one-way ANOVA. The Tukey 
multiple comparison test was used as post hoc analysis.  Differences were accepted as statistically significant at 
p<0.05. The assay sensitivity for IL-10 (3 pg/ml) is shown with a broken line. 
 
 
IL-1β result is shown in Figure 14 and Figure 15.  
Within the healthy, pain free group, the distribution of IL-1β levels was high (max. level of 
170 pg/ml, not shown in figure). Approximately 50% of the individual means in each group 
were below the assay sensitivity (15 pg/ml) (Figure 14). For 3 of 4 of those migraine patients 
with a mean over the detection limit, the mean IL-1β level decreased during attack (Figure 15 
A). Both low back pain patients with a mean over the detection limit had an elevated mean 
IL-1β level during pain (Figure 15 B). 
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Figure 14: IL-1β levels 
Serum IL-1β level for each patient is expressed as mean (pg/ml). Each spot in each group represent the mean 
(pg/ml) for one patient. IL-1β levels were compared between each group by using one-way ANOVA. The Tukey 
multiple comparison test was used as post hoc analysis.  Differences were accepted as statistically significant at 
p<0.05. The assay sensitivity for IL-1β (15 pg/ml) is shown with a broken line. 
 
 
 
Figure 15: IL-1β levels in migraineurs and low back pain patients 
Serum IL-1β level for each patient is expressed as mean (pg/ml). Each spot in each group represent the mean 
(pg/ml) for one patient and are marked with an individual patient number (eg. p.1). P.1 in A. and in B. is NOT 
the same patient.  Changes in mean IL-1β level, A. during migraine attack and attack free periods, and B. during 
low back pain and pain free periods, were analyzed using the two-tailed paired Student‘s t-test. Differences were 
accepted as statistically significant at p<0.05. 
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IL-17 result is shown in Figure 16 and Figure 17. 
The distribution of IL-17 levels was high within the healthy, pain free group and the migraine 
group (Figure 16). 52 %, 73 % and 43 % of the individual means, for the healthy, pain free 
individuals, migraine and low back pain patients respectively, were above the assay 
sensitivity (20 pg/ml). Changes of the individual IL-17 levels, during attack compared to 
attack free period, were not identical (Figure 17).  
 
 
Figure 16: IL-17 levels 
Serum IL-17 level for each patient is expressed as mean (pg/ml). Each spot in each group represent the mean 
(pg/ml) for one patient. IL-17 levels were compared between each group using one-way ANOVA. The Tukey 
multiple comparison test was used as post hoc analysis.  Differences were accepted as statistically significant at 
p<0.05. The assay sensitivity for IL-17 (20 pg/ml) is shown with a broken line. 
 
 
 
Figure 17: IL-17 levels in migraineurs 
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Serum IL-17 levels for each patient (marked with individual numbers) are expressed as mean (pg/ml). Changes 
of mean TNF-α level for each migraine patient are demonstrated with a line. Mean IL-17 levels were compared 
within the group using the two-tailed paired Student‘s t-test. Differences were accepted as statistically significant 
at p<0.05. 
 
3.3 ELISpot vs. ELISA 
Both the ELISpot and the ELISA results showed individual changes of the frequency of 
cytokine producing cells and the cytokine levels, during migraine attack compared to attack 
free period. Due to this, it became of interest to compare the ELISpot results and the ELISA 
results for the same patients. This comparison is shown for TNF-α in Figure 18. 
 
Both p.1 (blue) and p.8 (black) showed the same change, of mean frequency of cytokine 
producing cells (Figure 18 A) and mean cytokine levels (Figure 18 B), during attack. This was 
not the case for p.7 (red). The mean frequency of cytokine producing cells was elevated 
during migraine attack, while the mean cytokine level decreased.  
 
IL-17 results from the two assays were also interesting. No IL-17 producing cells were 
detected for any of the patients using the ELISpot assay (Figure 8). For all, except three 
migraine patients, changes in mean cytokine levels were detected (Figure 17). 
 
 
A. B.  
 
Figure 18: ELISpot vs. ELISA – changes of TNF-α production  
This figure shows changes of TNF-α production for three different migraine patients. Both A. ELISpot and B. 
ELISA results are shown. P.1 has the color blue, p.7 red and p.8 black. A. mean frequency of TNF-α secreting 
cells (per 100.000 cells). B. mean  cytokine levels (pg/ml)
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4. Discussion  
The first objective shifted to only concern migraine: to identify cytokines as possible specific 
biomarkers. The three other objectives remained unchanged: to define cytokine secretion as a 
possible inflammatory response to pain, to evaluate the use of ELISA assay and ELISpot 
assay, and to suggest improvements for future studies.  
These aspects are discussed in this chapter, starting with a general discussion of results, 
continuing with methods and then drawing conclusions. Improvements and future studies are 
addressed in the final section. 
 
The general discussion of results is primarily based on tendencies seen in graphs. Statistical 
analyses were performed, but to accurately assess the distribution within the different groups 
was challenging. This was mainly due to the small and unequal group sizes.  
 
 
4.1 Results 
 
4.1.1 Blood cytokine secreting cells in migraineurs 
A significantly higher frequency of TNF-α secreting cells than of IL-17 secreting cells (P = 
0.0047) was found (Figure 8). No IL-17 secreting cells were detected at all in migraineurs, 
despite that IL-17 is believed to have inflammation promoting functions. IL-17 is thought to  
induce pro-inflammatory cytokines and chemokines (Table 9, Appendix A), and has been 
shown to cooperate with TNF-α to enhance the inflammatory capacity of innate cells (60). It 
was expected to see a high frequency of IL-17 secreting cells in addition to TNF-α secreting 
cells in migraineurs. The results found in our study for IL-17 secreting mononuclear cells 
indicate that these cells are not a part of neurogenic inflammation in migraineurs. To the best 
of our knowledge no previous studies have linked IL-17 to migraine before. 
 
A tendency of lower frequency of IL-10 secreting cells than of TNF-α was observed (22-156 
vs. 83-456 secreting cells/100.000 cells). This is very interesting since TNF-α is considered to 
be a pain mediator in neurogenic inflammation and IL-10 has been shown to inhibit the 
hyperalgesic responses to TNF-α (39, 40, 42).  
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The ELISpot results do not indicate much regarding the relevance of cytokine producing cells 
in migraineurs. It would have been interesting to compare migraineurs with other headache 
patients, patients with other painful conditions and healthy, pain free individuals. 
Unfortunately this comparison was not done for the ELISpot analysis because of the limited 
timespan and budget of this study. A comparison of migraineurs with healthy, pain free 
individuals and low back pain patients was done for the ELISA assay (see section 4.1.2 Serum 
cytokine levels in migraineurs). To the best of our knowledge, no previous studies have 
investigated cytokine secreting peripheral blood mononuclear cells in migraineurs before.  
 
 
4.1.2 Serum cytokine levels in migraineurs 
We observed lower levels of MCP-1 in migraineurs and in low back pain patients, both during 
the pain period and the pain free period, compared to healthy, pain free controls (Figure 9). A 
significant difference was observed between the healthy, pain free group and the migraine, 
attack free group (P = 0.0223, one-way ANOVA). We suggest that MCP-1 may be of interest 
as a general pain marker, downregulated as a result of pain signals over time. The high 
distribution of mean MCP-1 levels seen within the groups made it of interest to investigate the 
individual mean changes during attack/pain in the migraineurs and low back pain patients. It 
may be a difference between the two painful conditions; 63% (5/8) of the migraine patients 
mean decreased during attack, while 75% (3/4) of the low back pain patients mean increased 
during pain (Figure 10). Previous studies have demonstrated that MCP-1 may be relevant for 
tension-type headache, but not for migraine (61, 62).  
 
A tendency of higher TNF-α levels in patients than in healthy, pain free individuals was 
observed (Figure 11). No difference was observed between migraineurs and low back pain 
patients. We suggest that TNF-α may be a general pain marker, upregulated in response to 
pain. It cannot be dismissed that an overexpression of TNF-α may contribute to the 
nociceptive activity during migraine. In 2010 Yilmaz et al. observed that the TNF-α -308 A 
allele was overrepresented in migraineurs compared to healthy controls. They also observed a 
significant increase of IL-1β +3953 T allele in migraineurs. They suggested that an 
overexpression of TNF-α and IL-1β in migraineurs would be expected (38). Our observation 
of TNF-α is in agreement with this suggestion.  
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A tendency of lower IL-10 levels in patients compared to healthy, pain free controls was 
observed (the majority of patients had undetectable levels, Figure 13). A trend also observed 
in CSF (62). This tendency is interesting because IL-10 has been shown to inhibit 
hyperalgesic responses to TNF-α (Table 9). As also observed for TNF-α and IL-10 secreting 
cells, IL-10 levels seem to be low when TNF-α levels are high (Figure 8, Figure 11 and 
Figure 13). Since no difference was observed between the migraine and the low back pain 
patients this may indicate that IL-10 is downregulated, and TNF-α upregulated, in response to 
pain in general. Previous studies have observed higher or similar IL-10 levels during migraine 
compared to healthy controls (24, 44, 45, 48). Fidan et al. (2006) observed an increase during 
attack compared to attack free period (45). This comparison could not be done in our study 
because the majority of the patient results were below the detection level. Undetectable IL-10 
levels seem to be a recurrent phenomenon (44, 52).  
 
No difference in IL-1β levels was observed in patients compared with healthy individuals 
(Figure 14). Approximately 50% of all individual means in all groups were undetectable. IL-
1β was rarely detected and at low levels in CSF as well (62). In contrast with our findings, 
TNF-α is thought to induce hyperalgesia mediated through the release of IL-1 and an 
overexpression of IL-1β would be expected in migraineurs (38, 40).  
 
For the rest of the 21 cytokines tested for, no differences were detected between or within the 
different groups (results not shown).  
 
A high distribution of results within the groups was observed for the majority of cytokines 
(eg. Figure 9 and Figure 16), as were undetectable levels (eg. Figure 13, Figure 14 and Figure 
16). Both elevated and decreased levels of cytokine production, during attack compared to 
attack free period, were observed within groups (eg. Figure 8, Figure 10 and Figure 12), 
indicating that changes of cytokine production may be patient dependent. One may speculate 
that the unequal distribution of age and gender within groups, the use of medications (triptans, 
NSAIDs, opoids) prior to blood sampling (Table 4), the possible transitory variation of 
cytokine levels and the heterogeneity of migraine may be reasons for the high distribution of 
results and the patient dependency observed. 
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A previous study found aging associated with significant changes in cytokine production. For 
some of these cytokines the changes were also gender specific (63). However, several studies 
have not found any correlation between age, gender and cytokine production in migraineurs 
(24, 48, 52).  
It is possible that the use of medication prior to blood sampling may have influenced the 
cytokine production. Triptans act like 5-HT agonists and both inhibit TG activation and block 
transmission in the TGVS. NSAIDs reduce perivascular neurogenic inflammation by affecting 
T-cells, neutrophils and macrophages. And opoids work as analgesics by inhibiting ascending 
pathways that carry pain information from primary sensory neurons and by activating 
descending pain control systems (64). In fact, Munno et al (2001) demonstrated an effect of 
sumatriptan on IL-10, IL-4 and IL-5 levels in migraineurs (48). 
It has been demonstrated a transitory variation of TNF-α levels at different times after 
migraine onset, where the highest levels were found within the first two hours (24, 46). 
Regarding IL-1β, IL-6 and IL-4, the results have been conflicting. The different individual 
cytokine levels observed in this present study may have been a result of blood samples not 
being collected at specific times. 
The high extent of undetectable levels among the 25 cytokines studied may be due to the fact 
that most cytokines are secreted and act at local sites and only enter the circulation when 
secreted in large amounts (65). Other possible reasons for the concentrations being too low for 
detection may be because cytokines have a short half-time, because of dilution in serum or 
because of consumption after secretion (45, 66).  
 
Despite having large sample sizes and following strict criteria for patient selection and 
sampling conditions, Bockowski et al. (2010) also demonstrated a high extent of undetectable 
levels and data not being normally distributed. Statistical analysis and finding significant 
differences was not feasible (52).   
 
The many conflicting results regarding cytokine levels in migraineurs seen throughout the last 
couple of years may be due to several reasons. The use of assay kits with different sensitivity 
levels, different criteria for patient selection, exclusion and sampling conditions, and due to 
different group sizes studied. 
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4.2 Methods 
 
4.2.1 Patient recruitment 
The exact number of headache patients admitted to Haukeland University Hospital in one year 
was not known prior to this study. Relatively few headache patients were hospitalized with 
acute headache this year. One year of patient recruitment was not sufficient to get groups 
consisting of 20 individuals.  
There may be several reasons for the low number of participants. Not all headache patients 
were sent to the Department of Neurology. Several patients were admitted during evening and 
nighttime, while the inclusion of patients could be administered only during daytime. Only 
one neurologist had the responsibility of identifying suitable patients for this study. The 
personal interviews and the laboratory work were carried out by one person only. Few 
tension-type patients were admitted to the hospital, probably because their headache is less 
severe and not disabling. Cluster headache is a rare condition and patients are rarely 
hospitalized because of relatively short lasting attacks (15-180min).  
In order to increase the number of participants the recruitment period could be expanded and 
the Department of Neurosurgery included. By having one person with the responsibility for 
personal interviews and one for the laboratory work, possible participants would not have 
been left out of the study as a consequence of no one being there to recruit them. Inclusion 
both day and night could also been an alternative.  
 
4.2.2 Sampling criteria 
Blood samples, during attack and pain period, were collected the first morning after 
hospitalization. For how long each patient had been in pain varied (from one hour to several 
days). The majority had taken medication (opioids, triptans and/or NSAIDs) prior to blood 
sampling (Table 4). As discussed earlier, different time of blood sampling and the use of 
medication may have influenced the blood cytokine levels.  
It could be ideal to exclude these variables in future studies by setting criteria for the time of 
sampling and avoid the use of medication. This could have been done in a prospective study 
with patients being recruited, informed and diagnosed prior to the study. On the other hand, 
this could make it even more difficult to recruit patients during attack and be guaranteed 
severe pain intensity at the time of sampling.  
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Criteria for the pain free samples were set prior to sampling. Samples were taken 1-2 months 
after hospitalization, during a pain free period, from both migraineurs and low back pain 
patients. Patients had been pain free for at least two days and the divers had not been training 
or diving, or had any complaints of pain, during the last two days before sampling. Not all 
patients met for control sampling (pain free samples) (Table 5). Not all became pain free 
during the sampling period and for some it was difficult to meet for personal reasons.  
 
4.2.3 PBMC sample storage 
It is not recommended to store PBMC samples over a longer period of time (˃ 1 week) at -
80°C due to the possibility of impaired PBMC recovery and viability upon thawing (55). 
Instead it is recommended to transfer the samples into a liquid nitrogen tank (≤ -132°C) after 
24-72 hours and not to store them for more than 6 months (55). Unfortunately this was not an 
option during the storage of patient PBMC samples because liquid nitrogen tanks were not 
available. Storage at -80°C for 1-2 weeks has been successful previously at the laboratory. 
Viable cells were counted after thawing. Each sample had a concentration of about 20 million 
cells/ml. Storage at -80°C for 1-2 weeks did not impair PBMC recovery and viability of 
importance for these experiments.  
 
4.2.4 ELISpot assay 
The experiments were performed according to the manufacturer‘s descriptions, with minor 
modifications. HTS HA plates were used instead of the PVDF-based membrane plates from 
the kits because it was easier to use. The PVDF-based membrane plates needed to be 
activated with alcohol, a critical step which made it difficult to coat several plates at the same 
time. This step was not needed for the HA plates. During development the PVDF-based 
membrane plates developed a darker background color than the HTS HA plates, which made 
it difficult to see when spots emerged and when to abort the development process (Figure 7). 
The number of spots that developed on the PVDF-based membrane plates was very high, 
making it difficult for the software to distinguish spots from each other and give an accurate 
count of cytokine secreting cells.  
 
According to recommendation from MabTech, different concentrations (cells/ml) of cell 
suspensions were tested for the different cytokines (results not shown). Concentrations used in 
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the experiments are listed in Table 7. Concentrations above these resulted in overcrowded 
wells and concentrations below these resulted in almost empty wells, making counting 
difficult. Two different concentrations were used in order to get a more representative mean 
of the frequency of cytokine secreting cells. 
 
During rinsing of the HA plates, 0.05% PBS-T and a vacuum manifold were used. This is a 
well-established and tested procedure at the Broegelmann laboratory when using HA plates. 
Millipore does not recommend exceeding 0.01% PBS-T, to prevent the possibility of leakage, 
or using a vacuum manifold since the plates does not require filtration (59, 67). No leakage of 
importance has been experienced at the lab using 0.05% PBS-T and vacuum manifold. The 
filtration step can be skipped in future experiments, making the rinsing step more convenient.  
 
After development the plates were left to dry for two days. When punching out the 
membranes, breakage was experienced around some of the edges. Two days may have been 
too long and resulted in too dry and crispy membranes. The software counted dark areas 
(broken bits) as spots, which resulted in unnecessary amount of work during quality control. 
For future experiments, leaving the plates to dry for one day is considered to be adequate. 
 
Each PBMC sample was stimulated with polyclonal activators to make sure that the test 
system functioned properly and to test that viable cytokine secreting cells were present. As 
shown in Table 8 the attack free samples from p.1, p.7 and p.8, plated on the same plate, were 
negative in the positive control wells for IL-10. Cells and the development process do not 
seem to have been the problem. The same samples were analyzed for TNF-α and IL-17, using 
the same enzyme conjugated streptavidin and development substrate, and they were positive. 
The only step that may have been the reason for the negative results is the coating. The 
coating antibody solutions used for the three different cytokines were not the same and may 
explain why these samples were positive for TNF-α and IL-17, but not for IL-10.  
The attack free sample from p.6 was negative in the positive control wells for all three 
cytokines, but the other samples on the same plate (p.1, attack and p.9, attack free) were 
positive. A possible reason for this may be that this particular sample needed longer 
development time. This was therefore a negative consequence of plating different samples on 
the same plate. 
For a total of four of five attack free samples, analyzed for IL-10, the test system did not 
function properly. No comparison of the frequency of IL-10 secreting cells during migraine 
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attacks and attack free periods could be done. This highlights the importance of having 
sample aliquots; if there were more samples, new experiments could have been done. 
 
4.2.5 ELISA assay 
The experiments were performed according to the manufacturer‘s descriptions without any 
modifications. Data was obtained for all samples and for all cytokines tested for. Some of the 
results are illustrated in Figure 9 to Figure 17 in section 3.2.1 Cytokine levels in migraine and 
low back pain patients, and discussed in section 4.1.2 Serum cytokine levels in migraineurs. 
 
4.2.6 ELISA vs. ELISpot 
The ELISpot assay is considered to be more sensitive than the ELISA assay; it detects 
cytokine secretion at single cell levels and immediate capture cytokines upon secretion. 
ELISA may fail to detect soluble cytokines accumulated in serum due to dilution, 
consumption or degradation of secreted cytokines (66). This is in agreement with our IL-10 
results. Mean frequencies of 22-156 secreting cells per 100.000 cells were detected, but a 
soluble IL-10 level (30 pg/ml) was only detected for one of the same migraine patients 
(Figure 8 and Figure 13).   
The ELISpot assay failed to detect any IL-17 secreting cells, while mean soluble IL-17 levels 
(19-71 pg/ml) were detected for all of the same migraine patients using the ELISA assay 
(Figure 8 and Figure 16). This suggests that low frequencies of cytokine secreting cells do not 
necessarily indicate low levels of soluble cytokines, and vice versa.  
In this context it is important to mention that peripheral blood mononuclear cells, such as 
lymphocytes, macrophages and monocytes, were the only cells tested for cytokine secretion 
using the ELISpot assay. This may be considered as a limitation of this method when looking 
at cytokines as possible biomarkers in blood for migraine. Several other cells, in addition to 
mononuclear cells, like mast cells in the dura, glia cells in the TG and arterial smooth muscle 
cells, are believed to contribute to the cytokine secretion and neurogenic inflammation in 
migraineurs. With the ELISA assay, serum concentrations of soluble cytokines were 
measured, including cytokines secreted from several cell sources (assuming the cells secreted 
enough cytokines to enter the circulation).  
TNF-α results (Figure 8 and Figure 11) did not clearly show a difference between frequency 
of cytokine secreting cells and levels of soluble cytokines within the migraine group. But the 
individual data revealed a difference (Figure 18, see p.7 (red)). An elevated frequency of 
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cytokine secreting cells was detected during attack, but a decreased level of soluble cytokines 
was detected.  
Despite the conflicting results observed for the two methods, they also showed some of the 
same tendencies for TNF-α; it was no difference between the attack and the attack free period 
and TNF-α production was higher than IL-10 production. 
 
 
4.3 Conclusions 
 
4.3.1 Cytokines as biomarkers for migraine 
This study did not reveal any distinct cytokines to be considered as specific biomarkers for 
migraine. Some interesting tendencies for MCP-1, TNF-α and IL-10 were seen though. A 
possible upregulation of TNF-α and downregulation of MCP-1 and IL-10 seem to be of 
relevance, if not specifically for migraine, at least for painful conditions in general. Further 
investigation of these cytokines and a comparison between migraineurs and patients with 
tension-type headache and cluster headache is of interest. 
 
4.3.2 ELISpot vs. ELISA 
It is difficult to tell which method that was best for studying cytokine production in 
migraineurs. The results obtained were not identical. The two methods provided information 
about cytokine production from different cell sources. The ELISpot assay revealed cytokine 
production from peripheral blood mononuclear cells. The ELISA assay revealed cytokine 
production from other additional cells, believed to be relevant for the neurogenic 
inflammation in migraineurs, by measuring cytokine levels in serum. Both methods had their 
advantages and disadvantages. Where one method failed to detect cytokine production the 
other one did not. Further comparisons have to be done. 
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4.4 Improvements and future perspectives 
 
It would have been better with larger groups (≥20), equal in size, in order to accurately assess 
the distribution within the different groups and to determine which statistical analyses to 
employ. Suggestions how to increase the number of participants could be to: 1. Extend the 
recruitment period (˃ 1 year). 2. Include patients both day and night.  3. Include several 
departments at the hospital. Another suggestion could be to do a multicenter study, including 
several hospitals and/or general physicians. Even though, this could compromise the 
homogeneity of sampling and analysis. 
 
Other suggestions for improvements could be to 1. Avoid variables that may affect cytokine 
levels, by setting criteria for sampling time and the use of medication. 2. Avoid a possible 
relation between age, gender and cytokine production, by having age and gender matched 
subgroups.  
 
In this study, comparison of cytokine levels in migraineurs with cluster headache patients and 
TTH patients was not accomplished. No cluster headache patients and only two tension-type 
headache patients agreed to participate. Future investigations of differences between the three 
headache syndromes and other painful conditions, such as low back pain, are of interest.  
To our knowledge few have done this comparison before. In 2008 Bø et al. compared CSF 
cytokine levels between migraineurs and episodic TTH patients. They suggested that MCP-1 
along with IL-10 assist in restoring homeostasis in TTH patients, but not in migraineurs (62). 
In 2009 Bockowski et al. suggested that there may be a difference between TTH patients and 
migraineurs regarding blood TNF-α levels. In 2010 Bockowski et al. did the same comparison 
for IL-4, IL-13 and IL-10, without definite conclusions (52).  
 
 
According to our findings, we suggest that TNF-α, MCP-1 and IL-10 are the most interesting 
cytokines to focus on in future studies, as biomarkers for migraine and as general pain 
markers. IL-1β and IL-17 may also be of interest. The high distribution of cytokine levels and 
the probable patient dependency seen in migraineurs, probably due to the heterogeneity of the 
disease and the fact that cytokine levels may be transitory, makes further investigation of 
interest. A suggestion is to investigate changes of cytokine levels during a longer period of 
time; before, during and after attack. A prospective study could help answering whether or not 
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each patient has his/her own cytokine pattern and if it is individual what kind of cytokine 
change that can be associated with migraine. This requires a more advanced study design with 
patients hospitalized over a longer period of time and with attacks being induced.  
 
If the heterogeneity of migraine is relevant for cytokine levels, it would be interesting to 
investigate differences of cytokine levels in migraineurs who have an effect of symptomatic 
drugs, like triptans, and in migraineurs who do not. This could be done with a prospective 
study, determining cytokine levels before, during, and after attack, both when using 
symptomatic drugs and when not. As mentioned earlier Munno et al (2001) have 
demonstrated an effect of sumatriptan on IL-10, IL-4 and IL-5 levels in migraineurs (48)
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Appendix A 
 
Inflammation 
Inflammation is a complex reaction of vascularized tissue, which involves extravascular 
accumulation of plasma proteins and leukocytes, that serves a protective function in 
controlling infections and promoting tissue repair (68). Macrophages already present in the 
tissues, like microglia in the brain, immediately begin to phagocytize invading pathogens and 
release molecular mediators (69, 70). These mediators contribute to the inflammatory 
response and the recruitment and activation of effector cells (70). Cytokines, regulatory 
proteins that play major roles in regulating the development and behavior of immune effector 
cells, are some of the mediators which are released (69, 70). They, in addition to other 
chemoattractants, promote the recruitment and increased production of other leukocytes, such 
as neutrophils and monocytes, and thereby further phagocytosis (70). Macrophages partially 
digest the phagocytized pathogens and induce the antigen products to T-lymphocytes and 
thereby activate them (71). They also secrete IL-1, which promotes further growth and 
reproduction of the specific lymphocytes. The activated T-cells proliferate and release active 
and specifically reacting T cells; memory T cells, helper T cells, cytotoxic T cells and 
suppressor T cells. Helper T cells form several protein mediators, cytokines, which act on 
other immune cells and bone marrow cell (71). Table 9 present some factors believed to play 
important roles during inflammation. 
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Table 9: Inflammatory factors 
This table presents some factors believed to play important roles during inflammation (39-42, 65, 71, 72). 
 
Cytokine Secreted from Effect 
   
IFN-γ T cells B-cell stimulation; T cell differentiation; Macrophage activation 
 
TNF-α Macrophages, T 
cells 
Induction of fever, IL-1, IL-6 and chemokines (e.g. IL-8); Synthesis of acute-
phase proteins by the liver; Increased vascular permeability and adhesion 
molecules on vascular endothelium (inflammation); Fibroblast proliferation; 
Activation of T-cells, B-cells and neutrophils; May induce dose-dependent 
hyperalgesia mediated by IL-1β release. 
 
GM-CSF Macrophages, T 
cells 
 
Increase of monocyte and granulocyte production by the bone marrow 
 
IL-1 Macrophages Induction of fever, chemokines (e.g. IL-8) and IL-6; Synthesis of acute-phase 
proteins by the liver; Increased vascular permeability and adhesion molecules 
on vascular endothelium (inflammation); Fibroblast proliferation; Activation 
of T-cells and B-cells; Platelet production; May induce dose-dependent 
hyperalgesia.  
 
IL-2 T cells Stimulation of growth and proliferation of cytotoxic and suppressor T cells 
and activation of T helper cells; Proliferation of B cells and antibody 
synthesis 
 
IL-3 T cells Lymphocyte growth factor 
 
IL-4 T cells Stimulation of B-cells and immunoglobulin production; Inhibition of IFN-γ-
mediated macrophage activation; May limit production of  IL-1β, IL-6, IL-8 
and TNF-α; May inhibit TNF-α induced hyperalgesia.  
 
IL-5 T cells Stimulation of B-cells and immunoglobulin production; Activation and 
increased production of eosinophils 
 
IL-6 Macrophages, T 
cells 
Induction of fever; Synthesis of acute-phase proteins by the liver; Increased 
vascular permeability; Platelet production; T cell and B cell activation; 
Increased immunoglobulin synthesis. May induce dose-dependent 
hyperalgesia.  
 
IL-10 Macrophages, T 
cells 
Inhibition of IL-12 production and expression of costimulators; May inhibit 
production of IL-1, IL-6, IL-8, GM-CSF and TNF-α; May inhibit 
hyperalgesic responses to TNF-α, IL-1β and IL-6. 
 
IL-12 Macrophages T cell differentiation; Stimulation of IFN-γ synthesis 
 
IL-13 T cells Stimulation of B-cells and immunoglobulin production 
 
IL-15 Macrophages T cell proliferation 
 
IL-17 T cells Increased chemokine production from endothelial cells and macrophages; 
Increased cytokine production from macrophages; GM-CSF and G-CSF 
production from epithelial cells 
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Appendix B 
 
Anamnese (pasientens sykehistorie) 
 
 
 
 
 
 
 
 
 
 
1) Kvinne                    Mann   
 
2.a) Har andre i familien migrene?    Ja         Nei           Hvem? 
 
 
2.b) Har andre i familien spenningshodepine?   Ja      Nei      Hvem?  
 
 
2.c) Har andre i familien klasehodepine?    Ja      Nei      Hvem?  
 
 
2.d) Har andre i familien annen hodepine?    Ja      Nei       Hvem?  
                                                                      
                                                                  Type hodepine  
 
 
3.a) Hvor gammel var du da du for første gang ble plaget med hodepine (av den art som 
førte til innleggelse)? 
 
                År 
 
 
3.b) Hvor mange hodepineanfall har du i måneden? 
 
                                     ganger i måneden 
 
 
3.c) Hvor mange timer/dager pleier hodepinen vare om gangen? 
 
 timer    dager  
 
 
 
 
 
Navn:                                                                                    Fødselsnr: 
20                 Dato:                                                                 Sted:                                      
  
 
 
  
  
  
                      
                      
  
  
                      
                      
                      
Nummer/adresse:                                                                 Deltakernr:                                
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3.d) Mener du det er noe som utløser hodepinen (som mat, drikke, stress, menstruasjon, 
fysiske anstrengelser, nakkebevegelser)? 
 
Ja            Nei 
 
Hvis ja, hva? 
 
 
 
 
 
 
 
 
 
 
 
 
 
Har du andre sykdommer?   Ja         Nei 
 
Hvis ja, hvilke? 
 
 
 
 
 
 
 
 
 
3.e) Hvilke lindrende, ikke-medikamentelle faktorer har vist seg å fungere for deg (eks. 
frisk luft, stille rom, fysisk aktivitet osv.) ? 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
6. Appendix 
 
58 
 
 
4) Hvilke tidligere medisinske undersøkelser (som f.eks MR, CT) har blitt utført i 
forbindelse med hodepineplagene og hva var resultatene? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.a) Bruker du smertestillende ved anfall?  Ja           Nei 
 
Navn på legemidler                                     Mengde (mg) 
 
 
 
 
 
 
 
 
 
5.b) Hvor mye bedre blir du etter å ha tatt smertestillende? 
 
Litt bedre                (ikke i stand til å utføre daglige gjøremål, må fortsatt holde sengen) 
 
Bedre                      (evnen til å utføre daglige gjøremål er delvis svekket) 
 
Mye bedre               (fungerer normalt) 
 
 
6.a) Bruker du forebyggende medisiner for hodepinen?   Ja          Nei 
 
Hvis ja, fyll ut: 
Undersøkelse 1: 
 
Resultat 1: 
 
 
Undersøkelse 2: 
 
Resultat 2: 
 
 
Undersøkelse 3: 
 
Resultat 3: 
 
 
Undersøkelse 4: 
 
Resultat 4: 
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Navn på legemidler                                    Daglig mengde (mg)     Fom. dato (dd.mm.år) 
 
 
 
 
6.b) Har antall hodepineanfall blitt redusert etter du begynte med nåværende 
forebyggende medisiner? 
 
Ja           Nei          Usikkert  
 
Hvis ja, 
 
Fra                             anfall i måneden 
 
Til  anfall i måneden 
 
 
6.c) Har hodepinen endret karakter etter du begynte med nåværende forebyggende 
medisiner (som redusert varighet og/eller styrke)? 
 
Ja           Nei          Usikkert  
 
Hvis ja, hvordan? 
 
 
 
 
 
 
 
 
 
 
6.d) Hvis du har brukt andre forebyggende medikamenter før, angis de her: 
 
Navn på legemidler                             Daglig mengde (mg)     Fom. – tom. dato(dd.mm.år) 
 
 
 
 
 
 
6.e) Hvorfor byttet du eventuelt forebyggende medisin? 
 
Ingen effekt 
 
Plagsomme/alvorlige bivirkninger?  
 
I så fall, hvilke? 
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Annen årsak: 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.a) Har du andre sykdommer?  Ja         Nei 
 
Hvis ja, hvilke? 
 
 
 
 
 
 
 
 
 
 
 
7.b) Bruker du forebyggende medisiner for denne/disse sykdommen(e)?   Ja         Nei 
 
 
Navn på legemidler                                    Daglig mengde (mg)      Fom. dato  (dd.mm.år)     
 
 
 
 
 
 
8) Røyker du? Ja        Nei  
 
 
8) Røyker du?   Ja         Nei 
 
 
9) Bruker du p-piller eller annen hormonell prevensjon? Ja         Nei 
 
Hvis ja, hvilken? 
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Appendix C 
 
Spørreskjema for registrering av akutt hodepine 
 
 
 
 
 
 
 
 
 
1.a) Når startet hodepinen som forårsaket innleggelse?    
  
                                                                            Dato (dd.mm.år)         Klokkeslett (time.min)  
 
 
 
1.b) Når ble du lagt inn pga denne hodepinen?  
          
                                                                           Dato (dd.mm.år)        Klokkeslett (time.min) 
 
 
 
 
1.c) Når var hodepinen borte?                        Dato (dd.mm.år)         Klokkeslett (time.min)  
 
 
 
 
 
2) Kontaktet du fastlege og/ eller legevakten på grunn av denne hodepinen?   Ja          Nei 
 
3.a) Har du (hyppig) hodepine også utenom den som var årsak til innleggelse? Ja        Nei 
 
3.b) Hvis ja, er hodepinen som førte til innleggelse annerledes enn din vanlige hodepine?       
 
Ja        Nei 
 
Hvis ja, på hvilken måte? 
 
 
 
 
 
 
 
 
4.a) Tok du dine vanlige medisiner hjemme på grunn av denne hodepinen (som førte til 
innleggelse)?       Ja         Nei  
Navn:                                                                                   Fødselsnr: 
20                     Dato:                                          Sted:                                             
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Hvis ja, 
 
Navn på legemidler                                    Mengde (mg)             Når tok du medisinene (kl)               
  
 
 
 
 
 
 
4.b) Hvor kraftig var hodepinen da du tok dine vanlige medisiner hjemme? 
 
Sett inn tall fra 0 til 10  
 
 
4.c) Hadde medisinene du tok hjemme noen effekt?  Ja        Nei 
 
5.a) Fikk du medisiner for hodepinen av din fastlege eller på legevakten?  Ja         Nei 
 
Navn på legemidler                                    Mengde (mg)             Når tok du medisinene (kl) 
 
 
 
 
 
 
 
5.b) Hvor kraftig var hodepinen da du var hos lege/legevakt? 
 
Sett inn tall fra 0 til 10 
 
 
5.c) Hadde medisinene du fikk av fastlege/legevakt noen effekt?   Ja           Nei 
 
6.a) Fikk du noen medisiner for hodepinen ved/etter innleggelse?    Ja         Nei 
 
Navn på legemidler                                    Mengde (mg)             Når tok du medisinene (kl) 
 
 
 
 
 
 
6.b) Hvor kraftig var hodepinen da du fikk medisiner ved/etter innleggelse? 
 
Sett inn tall fra 0 til 10 
 
 
6.c) Hadde medisinene du fikk på sykehuset noen effekt?     Ja         Nei 
                                                                  
                                                                  
  
                      
                      
                      
                      
                      
                      
                      
  
                      
                      
                      
                      
                      
                      
 
  
 
                      
  
                      
6. Appendix 
 
63 
 
 
7.a) Merket du i forbindelse med hodepineanfallet som medførte innleggelse 
(kryss av for det du merket): 
 
Forstyrrelser av syn  
 
Nummenhet i armer, kropp eller ansikt 
 
Forstyrrelser av tale 
 
Svimmelhet 
 
Lyd- og lysskyhet 
 
Kvalme og/eller oppkast 
 
Hode- og nakkestivhet   
 
Konjunktival injeksjon (rødt øye) 
 
Tåreflod 
 
Tett nese 
 
Rennende nese 
 
Svette i panne og/eller ansikt 
 
Miose (sammentrekning av pupill) 
 
Ptose (hengende øyelokk)  
 
Øyelokksødem 
 
Forverring ved moderat fysisk aktivitet  
 
 
Annet  
 
 
7.b) Har du nakkesmerter i forbindelse med hodepinen?       Ja            Nei 
 
7.c) Hvor i hodet var det vondt? 
 
Høyre side 
 
Venstre side 
 
Begge sider 
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Panne 
 
Bak øynene 
 
Tinningen  
 
7.d) Skiftet smerten side under anfallet?      Ja            Nei 
 
7.e) Hvordan var smerten? 
 
Pulserende (dunkende) 
 
Pressende/strammende 
 
Svært intens 
 
7.f) Forandret hodepinen karakter under anfallet?   Ja         Nei 
 
Hvis ja, forklar hvordan: 
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(Fylles ut av helsepersonell) 
 
Medikamenter brukt under det aktuelle hodepine anfallet, fyll ut mengde (mg) 
 
Hjemme: 
 
Triptaner 
Imigran 
Maxalt 
Naramig 
Zomig 
Relpax 
 
Opioider 
Paralgin Forte  
Petidin  
Morfin  
Paracet 
Kodein 
Subutex 
 
NSAIDS 
Ibux 
Naproxen 
Cataflam 
Voltaren 
 
Annet 
Nozinam 
 
 
Ved innleggelse: 
 
Triptaner 
Imigran 
Maxalt 
Naramig 
Zomig 
Relpax 
 
Opioider 
Paralgin Forte  
Petidin  
Morfin  
Paracet 
Kodein 
Subutex 
 
NSAIDS 
Ibux 
6. Appendix 
 
66 
 
Naproxen 
Cataflam 
Voltaren 
 
Annet 
Nozinam 
 
 
Hvilke undersøkelser ble utført ved innleggelse av pasient? 
 
MR            Resultat  
 
 
 
 
 
CT            Resultat 
 
 
 
 
 
Annet  
 
Hvis annet, hvilke(n) undersøkelse(r) 
 
 
 
 
 
 
 
 
Resultat(er) 
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Kryss av for hvilken hodepine som passer for pasienten og dens symptomer: 
 
Spenningshodepine 
Pressende/strammende hodepine som varer fra 30 min til 7 dager 
Mild eller moderat intensitet (vil hemme, men ikke forhindre normal daglig aktivitet) 
Forverres ikke av moderat fysisk aktivitet 
Bilateral lokalisasjon (kjennes på begge sider av hodet) 
Tidligere undersøkelser tyder ikke på en underliggende årsak til hodepinen 
 
Migrene med aura 
Synsforstyrrelser i form av mørke/blinde prikker, flekker eller annet forstyrrende mønster i 
synsfeltet (aura) 
Hodepinen følger auraen med et fritt intervall på mindre enn 60 min (hodepinen kan også 
begynne før eller under auraen) 
Pulserende hodepine med ensidig eller bilateral lokalisasjon  
Moderat eller betydelig intensitet (hemmer eller forhindrer normal daglig aktivitet) 
Forverres av moderat fysisk aktivitet 
Under hodepinen foreligger kvalme og/eller oppkast, og/eller lyd- og lysskyhet 
Hodepinen varer mellom 4 og 72 timer 
Tidligere undersøkelser tyder ikke på en underliggende årsak til hodepinen 
 
Migrene uten aura 
Pulserende hodepine med ensidig eller bilateral lokalisasjon  
Moderat eller betydelig intensitet (hemmer eller forhindrer normal daglig aktivitet) 
Forverres av moderat fysisk aktivitet 
Under hodepinen foreligger kvalme og/eller oppkast, og/eller lyd- og lysskyhet 
Hodepinen varer mellom 4 og 72 timer 
Tidligere undersøkelser tyder ikke på en underliggende årsak til hodepinen 
 
Klasehodepine 
Svært intens ensidig smerte lokalisert orbitalt eller supraorbitalt og/eller i tinningen 
Varer mellom 15 og 180 minutter ubehandlet 
Hodepine ledsages av minst en av de følgende tegn (må være på samme side som smerten) 
- konjunktival injeksjon 
- tåreflod 
- tetthet i nesen 
- renning fra nesen 
- svetting i panne og ansikt 
- miose 
- ptose 
- øyelokksødem 
 
 
 
 
 
 
 
……...………………………........      …………………....       …..……………………............ 
Sted                                                      Dato                               Signatur 
 
 
 
 
